NCT04350229View on ClinicalTrials.gov

Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

March 27, 2020

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions
Breast Cancer
Interventions
DRUG

Drug omission

Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.

OTHER

Control group

No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.

Trial Locations (1)

01246000

Vanessa Scontre, São Paulo

All Listed Sponsors
lead

Instituto do Cancer do Estado de São Paulo

OTHER

NCT04350229 - Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer | Biotech Hunter | Biotech Hunter